Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 4/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 3/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511514 | 1.00 | CTSS (0.41) | CTSSCTSKCTSBHDAC1GRIN2B | |
| SCHEMBL4503046 | 0.94 | HDAC1 (0.40) | CTSSCTSKCTSBHDAC1GRIN2B | |
| SCHEMBL4503048 | 0.94 | HDAC1 (0.40) | CTSSCTSKCTSBHDAC1GRIN2B | |
| SCHEMBL6058619 | 0.85 | GRIN2B (0.44) | HDAC1GRIN2BMEN1KMT2AGLS | |
| SCHEMBL6058625 | 0.85 | GRIN2B (0.44) | HDAC1GRIN2BMEN1KMT2AGLS | |
| SCHEMBL6058627 | 0.85 | GRIN2B (0.44) | HDAC1GRIN2BMEN1KMT2AGLS | |
| SCHEMBL6059332 | 0.76 | NAMPT (0.40) | HDAC1GRIN2BNAMPTBCL2GSK3B | |
| SCHEMBL6058862 | 0.73 | NAMPT (0.41) | HDAC1GRIN2BMEN1KMT2ANAMPT | |
| SCHEMBL6059375 | 0.73 | NAMPT (0.41) | HDAC1GRIN2BMEN1KMT2ANAMPT | |
| SCHEMBL949620 | 0.73 | NAMPT (0.48) | HDAC1GRIN2BMEN1KMT2AGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572817-B2 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| EP-1532111-B1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | METAP1, MPST, DNPEP | CTSS 126/4885CTSK 330/4885CTSB 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.